المؤلفون: Ziobrowska-Bech, Agnes, Winther-Larsen, Anne, Kremke, Britta, Parkner, Tina, Soendersoe Knudsen, Cindy

المصدر: Scandinavian Journal of Clinical & Laboratory Investigation; Feb-Apr2019, Vol. 79 Issue 1/2, p123-125, 3p

مصطلحات موضوعية: AUTOANTIBODIES, CHEMILUMINESCENCE immunoassay, TYPE 1 diabetes, PEDIATRICS, SERUM

مستخلص: The GAD65 and IA-2 antibodies (Abs) are biomarkers of the development of type 1 diabetes mellitus (T1DM) in both children and adults. The upper reference limit for the autoantibodies made by the manufacture was established on an adult Chinese population. Here, we established upper reference limits for Northern European adults and children in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. Serum samples from healthy Danish children (0-18 years) and adults (18-70 years) were analysed for GAD65Ab and IA-2Ab using MAGLUMI 800 Chemiluminescence Immunoassay (CLIA). The Kruskal-Wallis test was used for evaluating differences between gender and age groups. No gender or age differences were found for neither GAD65Ab nor IA-2Ab, and a combined upper reference limit for both children and adults could be established. An upper reference limit of 5.1 IU/mL was defined for GAD65Ab and 11.5 U/mL for IA-2Ab. Our results showed a substantial discrepancy with the reference limits established by the manufacturer. [ABSTRACT FROM AUTHOR]

: Copyright of Scandinavian Journal of Clinical & Laboratory Investigation is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Andrew Ustianowski, Nikos Kotsopoulos, Mark P. Connolly

المصدر: Journal of Medical Economics, 21(1), 19-26. Taylor & Francis Ltd

مصطلحات موضوعية: Complementary Therapies, Male, economic evaluation, ledipasvir, IMPACT, Cost-Benefit Analysis, Severity of Illness Index, Cohort Studies, Indirect costs, Tax revenue, 0302 clinical medicine, Cost of Illness, Health care, 030212 general & internal medicine, Prospective Studies, PERSPECTIVE, health care economics and organizations, Cost–benefit analysis, Public economics, Health Policy, Societal impact of nanotechnology, Hepatitis C, Health Care Costs, societal impact, Middle Aged, WORK PRODUCTIVITY, Models, Economic, Social protection, indirect cost, 030211 gastroenterology & hepatology, Female, Uridine Monophosphate, RIBAVIRIN, Adult, INTERFERON, VIRUS-INFECTION, sofosbuvir, public economic, 03 medical and health sciences, medicine, Humans, Fluorenes, business.industry, fiscal, GENOTYPE 1 INFECTION, Hepatitis C, Chronic, medicine.disease, United Kingdom, Early Diagnosis, Economic evaluation, HEALTH-CARE, Benzimidazoles, business

الوصف: Background: Hepatitis C (HCV) infection causes substantial direct health costs, but also impacts broader societal and governmental costs, such as tax revenue and social protection benefits. This study investigated the broader fiscal costs and benefits of curative interventions for chronic Hepatitis C (CHC) that allow individuals to avoid long-term HCV attributed health conditions.Methods: A prospective cohort model, assessing the long-term fiscal consequences of policy decisions, was developed for HCV infected individuals, following the generational accounting analytic framework that combines age-specific lifetime gross taxes paid and governmental transfers received (i.e. healthcare and social support costs). The analysis assessed the burden of a theoretical cohort of untreated HCV infected patients with the alternative of treating these patients with a highly efficacious curative intervention (ledipasvir/sofosbuvir [LDV/SOF]). It also compared treating patients at all fibrosis stages (Stages F0-F4) compared to late treatment (Stage F4).Results: Based on projected lifetime work activity and taxes paid, the treated cohort paid an additional 5,900 pound per patient compared to the untreated cohort. Lifetime government disability costs of 97,555 pound and 125,359 pound per patient for treated cohort vs no treatment cohort were estimated, respectively. Lifetime direct healthcare costs in the treated cohort were 32,235 pound, compared to non-treated cohort of 26,424 pound, with an incremental healthcare costs increase of 5,901 pound per patient. The benefit cost ratio (BCR) of total government benefits and savings relative to government treatment costs (including LDV/SOF) ranged from 1.8-5.6. Treating patients early resulted in 77% less disability costs, 43% lower healthcare costs, and 33% higher tax revenue.Conclusion: The ability to cure Hepatitis C offers considerable fiscal benefits beyond direct medical costs and savings attributed to reduced disability costs, public allowances, and improved tax revenue. Changes in parameters, such as productivity, wage growth, and tax rates, can influence the conclusions described here.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::617b8fd0d17129a7dcf08a84bda04d4bTest
https://doi.org/10.1080/13696998.2017.1371032Test

المؤلفون: Necmettin Akdeniz, Tugba Kevser Uzuncakmak, Serpil Oguztuzun, Emin Ozlu, Ayse Serap Karadag, Ozge Akbulak, Seyma Ozkanli

المساهمون: KKÜ, Kırıkkale Üniversitesi

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, medicine.medical_specialty, Histology, beta-Defensins, Antimicrobial peptides, Gastroenterology, 03 medical and health sciences, antimicrobial peptides, 0302 clinical medicine, Internal medicine, Psoriasis, medicine, Humans, human, Patient group, 030102 biochemistry & molecular biology, integumentary system, business.industry, Beta-defensin 2, Beta-defensin 1, Ultraviolet b, General Medicine, psoriasis, medicine.disease, Medical Laboratory Technology, Tissue expression, Gene Expression Regulation, 030220 oncology & carcinogenesis, Case-Control Studies, Immunohistochemistry, Female, beta defensin-1, beta defensin-2, business, phototherapy

الوصف: Uzuncakmak, Tugba Kevser Ustunbas/0000-0001-8057-3463 WOS: 000492502600001 PubMed: 31650859 We compared the expression profiles of antimicrobial peptides (AMPs) in psoriatic skin before and after narrow band ultraviolet B (nb-UVB) phototherapy and compared the levels to healthy controls. We studied 15 male and 12 female patients with psoriasis vulgaris, and 11 female and nine male control individuals. The patient group was treated with 24-36 sessions of nb-UVB phototherapy. Immunohistochemical staining for human beta defensin 1 (hBD-1) and human beta defensin 2 (hBD-2) expression of lesioned and control skin was performed prior to and following phototherapy. After phototherapy, the psoriatic area and severity index (PASI) decreased significantly in the treated patients compared to controls. The hBD-1 level was significantly higher in psoriasis patients than healthy controls. We found no statistically significant difference in hBD-1 and hBD 2 levels before and after phototherapy in the patient group. Although hBD-1 plays a role in psoriasis, levels of human beta defensin 1 and 2 are not affected significantly by phototherapy.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a957641c9f470fc461ee250e0f2c06Test
https://hdl.handle.net/20.500.12684/2590Test

المؤلفون: Antonia Squarcella, Camilla Aliberti, Lucia Manganaro, Enrica Marchionni, Antonio Pizzuti, Antonella Giancotti, Valentina D'Ambrosio, Renato Torre

مصطلحات موضوعية: Adult, 0301 basic medicine, medicine.medical_specialty, Pediatrics, pfeiffer syndrome, Genetic counseling, Limb Deformities, Congenital, Gestational Age, Prenatal diagnosis, 030105 genetics & heredity, Diagnosis, Differential, Young Adult, 03 medical and health sciences, Frontal Bossing, 0302 clinical medicine, medicine, Humans, cloverleaf skull, Receptor, Fibroblast Growth Factor, Type 1, Receptor, Fibroblast Growth Factor, Type 2, Hypertelorism, Ultrasonography, 030219 obstetrics & reproductive medicine, prenatal diagnosis, business.industry, FGFR1, FGFR2, Skull, Ultrasound, Obstetrics and Gynecology, Acrocephalosyndactylia, medicine.disease, Magnetic Resonance Imaging, Surgery, Radiography, medicine.anatomical_structure, Karyotyping, Mutation, Pediatrics, Perinatology and Child Health, Pfeiffer syndrome, Female, medicine.symptom, business, Genetic diagnosis, Abortion, Eugenic

الوصف: Pfeiffer syndrome (PS) is an autosomal dominant disorder caused by mutations in FGFR1 and FGFR2 genes. Given its wide range of clinical expression and severity, early prenatal diagnosis is difficult and genetic counseling is desirable. We report a literature review of all prenatal diagnosis of PS and a case report, with a focused description of ultrasound findings.After literature search, we selected 14 studies of antenatal diagnosis of PS. Prenatal ultrasound findings, outcome, maternal and obstetrical data and genetic tests were recorded and analyzed.A total of 18 cases including the one we present were selected. Among the most frequent sonographic features, skull shape anomalies were evident in 72.2% of cases, nasal abnormalities in 50%, proptosis and hypertelorism in 44.4% and frontal bossing in 22.2%. Thumbs' anomalies were present in 33.3% of cases and toes' abnormalities in 38.9%. In all cases, postnatal or postmortem examination confirmed the prenatal diagnosis of PS.We provide a literature review of prenatal diagnosis of PS to identify ultrasound features that may be supportive in the diagnosis of this rare disease, helping in making a differential diagnosis with the other possible craniosynostosis syndromes and in suggesting gene molecular testing.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d66a6c67f4221e273e10ec7da835ef29Test
http://hdl.handle.net/11573/907214Test

المؤلفون: Bircan Savran, İlay Gözükara, Sermin Tok, Ali Seven, Suna Kabil Kucur, Emel Kocak, Kadriye Beril Yüksel

مصطلحات موضوعية: 0301 basic medicine, Adult, medicine.medical_specialty, TGF-b1, 030232 urology & nephrology, Gestational Age, Hydronephrosis, Kidney, Group A, Gastroenterology, Group B, Transforming Growth Factor beta1, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Pregnancy, Internal medicine, medicine, Humans, Kidney Pelvis, Gynecology, Fetus, business.industry, Obstetrics and Gynecology, Gestational age, Biomarker, medicine.disease, fetal hydronephrosis, Fetal Diseases, 030104 developmental biology, pregnant woman, Case-Control Studies, Pediatrics, Perinatology and Child Health, Mann–Whitney U test, Biomarker (medicine), Female, business, Biomarkers, TGF-beta 1, Transforming growth factor

الوصف: WOS: 000368710600017
PubMed: 25902396
Objective: We aimed to identify a noninvasive marker for clinically significant fetal uropathies. To achieve this aim, we detected TGF (transforming growth factor)-1 serum level which rises in neonatal hydronephrosis, in pregnant patients with fetal hydronephrosis.Materials and methods: We evaluated 44 patients, all of whom were pregnant and had a gestational age between 20 and 30 weeks. Twenty-two patients had normal maternal renal ultrasound imaging and had a fetus with fetal hydronephrosis (Group A). The remaining twenty-two patients had normal maternal and fetal renal ultrasound imaging (Group B). The maternal serum levels of TGF-1 were measured with a sandwich enzyme-linked immunosorbent assay (ELISA) using a commercially available kit.Results: The median value for the study group was 55.90pg/mL (9.67574.45) and for the control group was 59.49pg/mL (12.49 +/- 402.04). There was no statistical difference in serum TGF-1 levels between the groups (p=0.769 - Mann-Whitney U test). In the study group, the diameter of the right renal pelvis was 5.7mm (5.1-8.9mm), while the diameter of left renal pelvis was 5.75mm (5.3-10.04mm).Conclusion: In our study, the circulating TGF-1 levels were not statistically different in the fetal hydronephrosis group when compared to the controls. According to our study, TGF-1 is not useful in the detection and follow-up of fetal hydronephrosis. We therefore require further studies involving larger groups with moderate or severe fetal hydronephrosis to detect the usefulness of the serum levels of TGF-1 in pregnant women with fetal hydronephrosis.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33d19bba7f8d6f849a1c5397567afd26Test
https://hdl.handle.net/20.500.12438/4036Test

المؤلفون: Mansur Kayataş, Gürsel Yildiz, Öztürk Özdemir, Ferhan Candan, Yahya Güngör

المساهمون: [Kayatas, Mansur -- Yildiz, Gursel -- Candan, Ferhan] Cumhuriyet Univ Hastanesi, Dept Nephrol, Fac Med, TR-58140 Sivas, Turkey -- [Gungor, Yahya] Cumhuriyet Univ Hastanesi, Fac Med, Dept Internal Med, TR-58140 Sivas, Turkey -- [Ozdemir, Ozturk] Cumhuriyet Univ Hastanesi, Fac Med, Dept Med Biol & Genet, TR-58140 Sivas, Turkey

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Genotype, medicine.medical_treatment, Peptidyl-Dipeptidase A, Critical Care and Intensive Care Medicine, Thrombophilia, Gastroenterology, chemistry.chemical_compound, Arteriovenous Shunt, Surgical, Renal Dialysis, Internal medicine, Plasminogen Activator Inhibitor 1, medicine, ACE gene polymorphism, PAI-1 4G/5G, Humans, arteriovenous fistula, Homocysteine, thrombophilia, Polymorphism, Genetic, hemodialysis, biology, business.industry, Factor V, Thrombosis, General Medicine, Middle Aged, medicine.disease, Blood Coagulation Factors, chemistry, Nephrology, Methylenetetrahydrofolate reductase, Plasminogen activator inhibitor-1, Case-Control Studies, Immunology, biology.protein, Prothrombin G20210A, Kidney Failure, Chronic, Female, Hemodialysis, business

الوصف: WOS: 000287485800010
PubMed ID: 21332339
Background: In this study, we investigated the relationship between early arteriovenous fistula (AVF) thrombosis with angiotensin-converting enzyme (ACE) gene and thrombophilic factor gene polymorphisms. Methods: Thirty-five patients who suffered from three or more fistula thrombosis episodes in the early period after AVF operation and 33 control patients with no history of thrombosis for at least 3 years were enrolled in this study. Results: Factor V G1691A Leiden, factor V H1299R (R2), prothrombin G20210A, factor XIIIV34L, beta beta-fibrinogen-455 G-A, glycoprotein IIIa L33P human platelet antigens (HPA-1), methylenetetrahydrofolate reductase C677T, and methylenetetrahydrofolate reductase A1298C gene polymorphisms were similar in both groups (p > 0.05). Plasminogen activator inhibitor 1 (PAI-1) 4G//5G genotype in the study group and 4G//4G genotype in the control group were significantly higher (p == 0.014). No significant difference was detected in terms of the 5G//5G genotype. With regard to the ACE gene polymorphism, the control group showed more ID genotype (19//33, 57.6%%), whereas the study group showed more DD genotype (17//35, 48.6%%). II genotype was similar in both groups (x

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c60908932ee519335ebf00e00006dfTest
https://hdl.handle.net/20.500.12418/9711Test

المؤلفون: Ibrahim Guney, M. Kemal Basarali, N. Yılmaz Selçuk, Huseyin Atalay, Lutfullah Altintepe, Sadık Büyükbaş

المساهمون: Selçuk Üniversitesi

مصطلحات موضوعية: Adult, Male, Adrenergic Antagonists, medicine.medical_specialty, medicine.drug_class, Aldosterone escape, Urology, Angiotensin-Converting Enzyme Inhibitors, Critical Care and Intensive Care Medicine, Transforming Growth Factor beta1, chemistry.chemical_compound, Mineralocorticoid receptor, Internal medicine, medicine, Humans, Prospective Studies, Mineralocorticoid Receptor Antagonists, Aldosterone, business.industry, Glomerulosclerosis, General Medicine, Middle Aged, medicine.disease, Fibrosis, Endocrinology, spironolactone, chemistry, Nephrology, Mineralocorticoid, Potassium-sparing diuretic, Disease Progression, Spironolactone, Kidney Failure, Chronic, Female, proteinuria, business, TGF-beta 1, chronic kidney disease, Kidney disease

الوصف: WOS: 000273987900002
PubMed: 19925284
Aims. Proteinuria and transforming growth factor beta (TGF-beta) are parameters that can lead to glomerulosclerosis and tubulointerstitial fibrosis. All components of the renin-angiotensin-aldosterone system (RAAS) activate the TGF-beta. Aldosterone may not be inhibited with angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) due to aldosterone escape. We aimed to evaluate the effect of spironolactone on parameters leading to fibrosis. Methods. This prospective study included 30 non-diabetic chronic kidney disease (CKD) patients treated with ACEIs and/or ARBs. The patients were divided into two groups that are similar in terms of demographic parameters. 25 mg of spironolactone was added to group 1 (n = 15) for six months, though it was not administered to group 2 (n = 15). Creatinine (U-Cr), protein (U-Prot), and TGF-beta 1 (U-TGF-beta 1) were measured in spot urine sample in the beginning of study and six months later. Results. Twenty-four patients completed the study. There were no significant changes in mean blood pressure, glomerular filtration rate, creatinine, albumin, and plasma aldosterone concentrations during the observation period in either group. U-Prot/U-Cr (mg/mg Cr) was reduced from 2.43 +/- 4.85 at baseline to 1.66 +/- 3.51 at sixth month (p = 0.003) in group 1. In addition, U-TGF-beta 1/U-Cr (ng/mg Cr) was also reduced from 22.50 +/- 6.65 at baseline to 17.78 +/- 10.94 at sixth month (p = 0.041) in the same group. U-TGF-beta 1/U-Cr and U-Prot/U-Cr ratios after the sixth month were not found significant compared with baseline values in group 2. Conclusion. Spironolactone reduced both proteinuria and urinary TGF-beta 1 excretion in CKD patients. We consider that spironolactone would be beneficial to prevent progression of renal fibrosis in CKD.
Ali Raif Drug Industry A.C.
This study was supported by Ali Raif Drug Industry A.C. for providing TGF-beta 1 and aldosterone kits.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f756b9a76f3c135b834003813eb952b6Test
https://hdl.handle.net/20.500.12395/23284Test

المؤلفون: Åsa L. Lethagen, Carina Törn, Fariba Vaziri-Sani, Kristian Lynch, Åke Lernmark, Jared Radtke, Shilpa Oak, Carl.-D. Agardh, Christiane S. Hampe, Mona Landin-Olsson, Corrado M. Cilio, Eva Örtqvist

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Adolescent, Immunology, 030209 endocrinology & metabolism, Zinc Transporter 8, Disease, Autoantibody titers, Clinical onset, Gastroenterology, Article, Statistics, Nonparametric, Cohort Studies, Radioligand Assay, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Protein Isoforms, Immunology and Allergy, Longitudinal Studies, Age of Onset, Child, Cation Transport Proteins, Autoantibodies, 030304 developmental biology, 0303 health sciences, Type 1 diabetes, business.industry, Autoantibody, Antibody titer, medicine.disease, Titer, Diabetes Mellitus, Type 1, Endocrinology, Cohort, Female, business

الوصف: Autoantibodies to the islet-specific zinc transporter isoform 8 (ZnT8) are detected in the majority of type 1 diabetes patients prior to and at clinical diagnosis. The presence of ZnT8Ab after diagnosis has not been investigated. This study analyzed the autoantibody response to ZnT8 in regard to age at onset and disease duration. Two new onset type 1 diabetes patient cohorts with different age distributions at onset (2–17 and 15–34 years of age at onset), a longitudinal subset of the younger type 1 diabetes patient cohort (n = 32), and a cohort of GAD65Ab-positive LADA patients (n = 47) was analyzed for the presence of autoantibodies directed to the two major isoforms, ZnT8-Arginine (ZnT8R) and ZnT8-Tryptophan (ZnT8W). The majority of type 1 diabetes patients tested positive for ZnT8Ab to both isoforms. ZnT8Ab titers were significantly higher in the younger type 1 diabetes patients as compared with the older cohort (ZnT8RAb at a median of 148 and 29 U/ml, respectively, p < 0.001) (ZnT8WAb at a median of 145 and 58 U/ml, respectively, p < 0.01). ZnT8RAb and ZnT8WAb titers were significantly lower in the LADA patients (ZnT8RAb at a median of 14 U/ml, ZnT8WAb at a median of 25 U/ml) as compared with either type 1 diabetes cohorts. In our longitudinal analysis of type 1 diabetes patients after clinical diagnosis, ZnT8Ab levels to both isoforms declined significantly during the initial year of disease (ZnT8RAb from a median of 320–162 U/ml, p = 0.0001; ZnT8WAb from a median of 128–46 U/ml, p = 0.0011). The antibody titers further declined during the following 4 years (p < 0.0001). We conclude that ZnT8Ab presents a useful marker for type 1 diabetes, especially in younger patients at disease diagnosis.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685384320d0d4df25db331b5cba73eaeTest